Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Ildong Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    A249420   KR7249420001

ILDONG PHARMACEUTICAL CO., LTD.

(A249420)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Il Dong Pharmaceutical Starts Clinical Trial of COVID-19 Drug

11/29/2021 | 06:19am EST


ę MT Newswires 2021
All news about ILDONG PHARMACEUTICAL CO., LTD.
2021South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills
MT
2021Il Dong Pharmaceutical Starts Clinical Trial of COVID-19 Drug
MT
2021ILDONG PHARMACEUTICAL : starts Phase 1 study of new diabetes therapy in Germany
AQ
2021Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany
CI
2021Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 100 billion in fundi..
CI
2021Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 100 billion in..
CI
2019Ildong Pharmaceutical Co., Ltd. Enters into Co-Promotion Agreement with GSK Consumer He..
CI
2017AntriaBio, Inc. announced that it has received $13 million in funding from Aju Pharm Co..
CI
2017AntriaBio, Inc. announced that it expects to receive $15 million in funding
CI
More news
Financials
Sales 2020 562 B 469 M 469 M
Net income 2020 -13 019 M -10,9 M -10,9 M
Net Debt 2020 80 692 M 67,4 M 67,4 M
P/E ratio 2020 -34,5x
Yield 2020 -
Capitalization 742 B 619 M 620 M
EV / Sales 2019 0,88x
EV / Sales 2020 0,94x
Nbr of Employees 1 385
Free-Float 53,9%
Chart ILDONG PHARMACEUTICAL CO., LTD.
Duration : Period :
Ildong Pharmaceutical Co., Ltd. Technical Analysis Chart | A249420 | KR7249420001 | MarketScreener
Technical analysis trends ILDONG PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Woong-Sub Yoon President, Chief Executive Officer & Director
Gyu-Seong Kang Chief Financial Officer & Director
Jin-Shik Seo Chief Operating Officer & Vice President
Chang-Rok Seo Independent Director
Nam-Jong Baek Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ILDONG PHARMACEUTICAL CO., LTD.-7.14%619
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963